Eun Ji Ro

Eun Ji Ro

Auto-generated profile, based on publicly available information

Eun Ji Ro

Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, Korea

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
YCYong-Hee Cho
Yong-Hee Cho
EREun Ji Ro
Eun Ji Ro
JYJeong-Su Yoon
Jeong-Su Yoon
TMTomohiro Mizutani
Tomohiro Mizutani
DKDong-Woo Kang
Dong-Woo Kang
KCKang-yell Choi
Kang-yell Choi
5-Fluorouracil (5-FU) remains the first-line treatment for colorectal cancer (CRC). Although 5-FU initially de-bulks the tumor mass, recurrence after chemotherapy is the barrier to effective clinical outcomes for CRC patients. Here, we demonstrate that p53 promotes WNT3 transcription, leading to activation of the WNT/β-catenin pathway in ApcMin/+/Lgr5EGFP mice, CRC patient-derived tumor organoids (PDTOs) and patient-derived tumor cells (PDCs). Through this regulation, 5-FU induces activation and enrichment of cancer stem cells (CSCs) in the residual tumors, contributing to recurrence after treatment. Combinatorial treatment of a WNT inhibitor and 5-FU effectively suppresses the CSCs and reduces tumor regrowth after discontinuation of treatment. These findings indicate p53 as a critical mediator of 5-FU-induced CSC activation via the WNT/β-catenin signaling pathway and highlight the significance of combinatorial treatment of WNT inhibitor and 5-FU as a compelling therapeutic strategy to improve the poor outcomes of current 5-FU-based therapies for CRC patients.

7 April 2013 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
EREun Ji Ro
Eun Ji Ro
PCPu-Hyeon Cha
Pu-Hyeon Cha
HKHyun-Yi Kim
Hyun-Yi Kim
YCYong-Hee Cho
Yong-Hee Cho
JPJung-Won Park
Jung-Won Park
KCKang-yell Choi
Kang-yell Choi